RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+2.78%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$1.04B
AUM Growth
+$1.04B
(-1.3%)
Cap. Flow
+$11.3M
Cap. Flow
% of AUM
1.09%
Top 10 Holdings %
Top 10 Hldgs %
35.44%
Holding
98
New
14
Increased
36
Reduced
31
Closed
5
Top Buys
| 1 |
UnitedHealth
UNH
|
$33M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$10.5M |
| 3 |
Danaher
DHR
|
$9.37M |
| 4 |
Edwards Lifesciences
EW
|
$9.01M |
| 5 |
Elevance Health
ELV
|
$8.83M |
Top Sells
| 1 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$20.8M |
| 2 |
Cigna
CI
|
$20.8M |
| 3 |
Tenet Healthcare
THC
|
$20.1M |
| 4 |
Medtronic
MDT
|
$9.21M |
| 5 |
Natera
NTRA
|
$8.99M |
Sector Composition
| 1 | Healthcare | 99.92% |
| 2 | Industrials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
UnitedHealth
UNH
$281B
| $53.6M | 5.15% | 105,300 +64,800 | +160% | +$33M |
|
|
2
Elevance Health
ELV
$71.8B
| $46.5M | 4.46% | 85,800 +16,300 | +23% | +$8.83M |
|
3
Boston Scientific
BSX
$156B
| $45.8M | 4.4% | 595,000 +13,000 | +2% | +$1M |
|
4
Eli Lilly
LLY
$657B
| $42.6M | 4.09% | 47,000 -7,175 | -13% | -$6.5M |
|
5
Regeneron Pharmaceuticals
REGN
$61.5B
| $33.6M | 3.23% | 32,000 -2,300 | -7% | -$2.42M |
|
6
AbbVie
ABBV
$372B
| $32.4M | 3.11% | 189,000 -500 | -0.3% | -$85.8K |
|
|
7
Tenet Healthcare
THC
$16.3B
| $30.5M | 2.92% | 229,000 -151,000 | -40% | -$20.1M |
|
8
Oscar Health
OSCR
$4.31B
| $30.2M | 2.9% | 1,906,611 +215,089 | +13% | +$3.4M |
|
9
Cooper Companies
COO
$13.4B
| $27.1M | 2.6% | 310,000 +9,000 | +3% | +$786K |
|
10
Intuitive Surgical
ISRG
$170B
| $26.9M | 2.58% | 60,500 +10,000 | +20% | +$4.45M |
|
11
Procept Biorobotics
PRCT
$2.23B
| $26.9M | 2.58% | 440,000 -47,063 | -10% | -$2.88M |
|
12
Becton Dickinson
BDX
$55.3B
| $26.4M | 2.54% | 113,000 -3,000 | -3% | -$701K |
|
13
HCA Healthcare
HCA
$94.5B
| $26.3M | 2.53% | 82,000 -18,000 | -18% | -$5.78M |
|
14
Vertex Pharmaceuticals
VRTX
$100B
| $25.3M | 2.43% | 54,000 -2,500 | -4% | -$1.17M |
|
|
15
Cigna
CI
$80.3B
| $24.5M | 2.35% | 74,171 -63,000 | -46% | -$20.8M |
|
16
Merck
MRK
$210B
| $21.7M | 2.08% | 175,000 -43,500 | -20% | -$5.39M |
|
|
17
Alnylam Pharmaceuticals
ALNY
$58.5B
| $20.8M | 1.99% | 85,500 +43,200 | +102% | +$10.5M |
|
18
BioMarin Pharmaceuticals
BMRN
$11.2B
| $20.7M | 1.99% | 251,500 +14,000 | +6% | +$1.15M |
|
19
Biogen
BIIB
$19.4B
| $19.7M | 1.89% | 84,800 +28,000 | +49% | +$6.49M |
|
20
McKesson
MCK
$85.4B
| $17.5M | 1.68% | 30,000 -14,000 | -32% | -$8.18M |
|
|
21
Natera
NTRA
$23.1B
| $17M | 1.63% | 157,000 -83,000 | -35% | -$8.99M |
|
|
22
Medtronic
MDT
$119B
| $16.4M | 1.57% | 208,000 -117,000 | -36% | -$9.21M |
|
23
Gilead Sciences
GILD
$140B
| $16.4M | 1.57% | 238,500 +111,500 | +88% | +$7.65M |
|
24
Abbott
ABT
$231B
| $15.1M | 1.45% | 145,000 -40,000 | -22% | -$4.16M |
|
25
Royalty Pharma
RPRX
$15.6B
| $14.4M | 1.38% | 544,697 | – | – |
|